Edasalonexent Inhibitor

MBS5754816 is an inhibitor targeting Edasalonexent. Edasalonexent is an orally bioavailable inhibitor of NF-kappaB.

Hammers DW, et al. Disease-modifying effects of orally bioavailable NF-kappaB inhibitors in dystrophin-deficient muscle. JCI Insight. 2016 Dec 22;1(21):e90341.
Hammers DW, et al. Disease-modifying effects of orally bioavailable NF-kappaB inhibitors in dystrophin-deficient muscle. JCI Insight. 2016 Dec 22;1(21):e90341.
Donovan JM, et al. A Novel NF-kappaB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying treatment, for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects. J Clin Pharmacol. 2017 May;57(5):627-639.
Donovan JM, et al. A Novel NF-kappaB Inhibitor, Edasalonexent (CAT-1004), in Development as a Disease-Modifying treatment, for Patients With Duchenne Muscular Dystrophy: Phase 1 Safety, Pharmacokinetics, and Pharmacodynamics in Adult Subjects. J Clin Pharmacol. 2017 May;57(5):627-639.

Small volumes of Edasalonexent, inhibitor vial(s) may occasionally become entrapped in the seal of the product vial during shipment and storage. If necessary, briefly centrifuge the vial on a tabletop centrifuge to dislodge any liquid in the container`s cap. Certain products may require to ship with dry ice and additional dry ice fee may apply.